Examples of 'ranibizumab' in a sentence
Meaning of "ranibizumab"
ranibizumab (adjective) - Refers to a medication used to treat certain eye conditions. It is not an English word but a term related to pharmaceuticals and healthcare
Show more definitions
- A monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic.
How to use "ranibizumab" in a sentence
Basic
Advanced
ranibizumab
It contains the active substance called ranibizumab.
For ranibizumab no clinical data on exposed pregnancies are available.
All patients were retreated with ranibizumab.
Ranibizumab is contraindicated in patients with ocular or periocular infections.
Treatment with intravitreal injections of ranibizumab was indicated.
Serum antibodies to ranibizumab were detected in some animals in many studies.
The dosing schedule is the same as for ranibizumab.
Bilateral intravitreal administration of ranibizumab to cynomolgus monkeys at doses between.
Lucentis is a medicine that contains the active substance ranibizumab.
The dosage for ranibizumab can be in any amount necessary.
Some reviews conclude that similar results are obtained using either bevacizumab or ranibizumab.
Serum and vitreous antibodies to ranibizumab were found in a subset of treated animals.
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia.
Months after the last dose of ranibizumab before conceiving a child.
The effect of ranibizumab treatment was similar irrespective of the presence of retinal ischaemia.
See also
Subjects randomized to sham injections follow the same schedule as subjects receiving ranibizumab.
Pack containing one glass vial of ranibizumab with chlorobutyl rubber stopper.
Ranibizumab is a antibody fragment derived from the same parent mouse antibody as bevacizumab.
The safety and efficacy of ranibizumab have not yet been studied in paediatric patients.
The active substance in Lucentis is ranibizumab.
Ranibizumab is an affinity maturated Fab fragment derived from bevacizumab.
Lucentis is supplied as a pack containing one glass vial of ranibizumab with chlorobutyl rubber stopper.
The effect of ranibizumab on CNV lesion size and leakage was assessed in secondary endpoints.
We opted for a new intravitreal injection of ranibizumab in the RE.
Ranibizumab is a humanised monoclonal antibody fragment produced in Escherichia coli cells by recombinant DNA technology.
Pregnancy There are no data from the use of ranibizumab in pregnant women.
Ranibizumab is commercially available under the trademark LUCENTIS.
The PDS continuously delivers a special formulation of ranibizumab over time.
Overall, ranibizumab treatment was well tolerated.
A generally favorable safety profile was observed for both EYLEA and ranibizumab.
No difference was found in VA outcomes after ranibizumab treatment among the different CFH genotypes.
This increased incidence was comparable between patients treated with ranibizumab and Eylea.
By blocking this factor, ranibizumab reduces the growth of the blood vessels and leakage.
The PDS is uniquely designed to continuously deliver a specialized formulation of ranibizumab over time.
If you are allergic ( hypersensitive ) to ranibizumab or any of the other ingredients of Lucentis.
More preferably the anti-VEGF antibody is bevacizumab or ranibizumab.
In addition, ranibizumab inhibited vascular leakage from the CNV lesions.
Furthermore, many undesirable side effects appear during treatment, particularly with ranibizumab.
Ranibizumab was developed and is marketed by Genentech under the trade name Lucentis ®.
Retinal vein occlusion and macular edema - critical evaluation of the clinical value of ranibizumab.
Ranibizumab binds to multiple VEGF-A isoforms.
In a further aspect, the VEGF inhibitor is bevacizumab or ranibizumab.
Therefore, they believe Ranibizumab is more effective and safer than Bevacizumab.
The port delivery system ( PDS ) is designed to continuously release a special formulation of ranibizumab.
Group III vPDT - patients were allowed to receive ranibizumab treatment as of Month 3.
Ranibizumab has been designed to block a substance called vascular endothelial growth factor A VEGF-A.
What Lucentis contains - The active substance is ranibizumab.
Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A VEGF-A.
The pharmaceutical composition of example D1, wherein the antibody is ranibizumab.
A PK / PD analysis showed no clear relationship between systemic ranibizumab concentrations and systemic VEGF concentrations.
